Successful treatment of transient acantholytic dermatosis with systemic steroids.
A sixty-year-old man, developed 2-5 mm sized, hyperemic, itchy papules, vesicles, erosions and crusts on hyperemic base on his chest, abdomen, back, gluteal region, and proximal sites of his upper and lower extremities. The direct and indirect immunoflurescence tests were negative. Histology revealed extensive acantholysis in the epidermis in the following forms: pemphigus vulgaris-like suprabasal acantholysis, Darier-like acantholytic dyskeratosis with corps ronds, Hailey-Hailey-like suprabasal clefts, and pemphigus foliaceus-like superficial acantholysis with spongiosis. Using systemic steroids, topical drying, and reepithelising therapy, the patient was cured. He was symptom-free the first, fourth, and thirteenth months after finishing steroid therapy. We review the literature and the new subdivision of the disease according to the histological and clinical features.
Erös
N
N
Department of Dermatology, Semmelweis Hospital, Miskolc, Hungary.
Kovács
A
A
Károlyi
Z
Z
D000051:Acantholysis / Q000188:drug therapy* / Q000473:pathology; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D007644:Darier Disease / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004817:Epidermis / Q000473:pathology; D019085:Fluorescent Antibody Technique, Direct; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D006940:Hyperemia / Q000473:pathology; D007642:Keratosis / Q000473:pathology; D008297:Male; D008622:Merbromin / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010392:Pemphigus / Q000473:pathology; D016506:Pemphigus, Benign Familial / Q000473:pathology; D011239:Prednisolone / Q000627:therapeutic use*; D012459:Salicylates / Q000627:therapeutic use
D000891:Anti-Infective Agents, Local; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003879:Dermatologic Agents; D005938:Glucocorticoids; D012459:Salicylates; D011239:Prednisolone; D008622:Merbromin